92 related articles for article (PubMed ID: 1963579)
1. Serum alpha-1-proteinase inhibitor with abnormal properties in ovarian cancer.
Thompson S; Wong E; Cantwell BM; Turner GA
Clin Chim Acta; 1990 Dec; 193(1-2):13-25. PubMed ID: 1963579
[TBL] [Abstract][Full Text] [Related]
2. Decreased branching, increased fucosylation and changed sialylation of alpha-1-proteinase inhibitor in breast and ovarian cancer.
Goodarzi MT; Turner GA
Clin Chim Acta; 1995 May; 236(2):161-71. PubMed ID: 7554283
[TBL] [Abstract][Full Text] [Related]
3. Fucosylated forms of alpha-1-antitrypsin that predict unresponsiveness to chemotherapy in ovarian cancer.
Thompson S; Guthrie D; Turner GA
Br J Cancer; 1988 Nov; 58(5):589-93. PubMed ID: 3265332
[TBL] [Abstract][Full Text] [Related]
4. Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms.
Turner GA; Goodarzi MT; Thompson S
Glycoconj J; 1995 Jun; 12(3):211-8. PubMed ID: 7496134
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of abnormally-fucosylated haptoglobins in cancer sera.
Thompson S; Turner GA
Br J Cancer; 1987 Nov; 56(5):605-10. PubMed ID: 3426924
[TBL] [Abstract][Full Text] [Related]
6. Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer.
Thompson S; Dargan E; Turner GA
Cancer Lett; 1992 Sep; 66(1):43-8. PubMed ID: 1451094
[TBL] [Abstract][Full Text] [Related]
7. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.
Scambia G; Benedetti Panici P; Perrone L; Sonsini C; Giannelli S; Gallo A; Natali PG; Mancuso S
Br J Cancer; 1990 Jul; 62(1):147-51. PubMed ID: 2167724
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of ovarian cancer. New approaches to treatment.
Smith JP; Rutledge F; Wharton JT
Cancer; 1972 Dec; 30(6):1565-71. PubMed ID: 4345098
[No Abstract] [Full Text] [Related]
10. Serum levels of vitamins A and E in women with ovarian cancer.
Heinonen PK; Koskinen T; Tuimala R
Arch Gynecol; 1985; 237(1):37-40. PubMed ID: 2996448
[TBL] [Abstract][Full Text] [Related]
11. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
[TBL] [Abstract][Full Text] [Related]
12. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS.
Wu J; Xie X; Liu Y; He J; Benitez R; Buckanovich RJ; Lubman DM
J Proteome Res; 2012 Sep; 11(9):4541-52. PubMed ID: 22827608
[TBL] [Abstract][Full Text] [Related]
13. [Intratumor chemotherapy of patients with cancer of the ovaries].
Vinokurov VL; Mitrokhina MV
Vopr Onkol; 1983; 29(8):58-61. PubMed ID: 6310891
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of spirogermanium in advanced ovarian malignancy.
Tropé C; Mattsson W; Gynning I; Johnsson JE; Sigurdsson K; Orbert B
Cancer Treat Rep; 1981; 65(1-2):119-20. PubMed ID: 6261944
[TBL] [Abstract][Full Text] [Related]
15. Tumor associated trypsin inhibitor and CA-125 during treatment of mucinous ovarian cancer in 2 patients.
Mogensen O
Eur J Cancer; 1991; 27(9):1180-1. PubMed ID: 1659852
[No Abstract] [Full Text] [Related]
16. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
[TBL] [Abstract][Full Text] [Related]
17. [The evaluation of the efficacy of adjuvant laferon therapy in the combined treatment of patients with ovarian cancer based on the monitoring of the tumor marker Ca-125 in the blood serum].
Zhyl'chuk VIe; Alistratov OV; Vorontsova AL
Lik Sprava; 1998; (2):137-9. PubMed ID: 9670686
[TBL] [Abstract][Full Text] [Related]
18. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
Markman M; Kennedy A; Kim J
Gynecol Oncol; 2001 Dec; 83(3):593-5. PubMed ID: 11733977
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
20. [Current status and future developments in chemotherapy of advanced epithelial ovarian cancers (author's transl)].
Szepesi T
Wien Klin Wochenschr; 1981 Apr; 93(8):251-5. PubMed ID: 6266166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
